Arnaud E, Molina F, Mendoza M, Fuente del Campo A, Ortiz-Monasterio F
Unité de Chirurgie Cranio-Faciale, Hôpital Necker-Enfants-Malades, Paris, France.
Ann Chir Plast Esthet. 1998 Feb;43(1):40-50.
Several biological materials have been analyzed in combination with osteo-inductive growths factors to determine whether such a system can replace bone grafting in surgical practice. Efforts have been aimed at the discovery of the best carriers and delivery systems. We present the results of the surgical treatment of 11 cranio-maxillo-facial defects in 9 patients using a combination of natural coral skeleton (NCS in blocks or granules), human fibrin glue and transforming growth factor beta-1 (TGF-beta 1) as a composite bone substitute. Three patients were initially excluded because of early extrusion of the materials due to a technical error. Clinical and radiological evaluation was performed in all cases, with the patient acting as his own control. Clinical firmness and radiological mineralization occurred in three quarters of cases. New bone formation was confirmed histologically in two of these patients. Clinically the initial results remained stable over a three years follow-up with staged surgical procedures performed on a number of patients. None of the patients suffered any detrimental effect from implantation of the bone substitute. Although the numbers in these series are limited, the association of TGF-beta 1, human fibrin glue and NCS represented an interesting step, although the clinical results could be improved. Important factors in the success of this technique appeared to be stabilisation of the biological materials, quality and asepsis of the surrounding tissue and the dose of growth factor.
已经结合骨诱导生长因子对几种生物材料进行了分析,以确定这样的系统在外科手术中是否可以替代骨移植。研究工作旨在发现最佳的载体和递送系统。我们展示了9例患者中11处颅颌面缺损的手术治疗结果,使用天然珊瑚骨架(块状或颗粒状的NCS)、人纤维蛋白胶和转化生长因子β-1(TGF-β1)的组合作为复合骨替代物。3例患者最初因技术失误导致材料早期挤出而被排除。所有病例均进行了临床和放射学评估,以患者自身作为对照。四分之三的病例出现了临床稳固和放射学矿化。其中2例患者经组织学证实有新骨形成。临床上,在对一些患者进行分期手术的三年随访中,初步结果保持稳定。没有患者因植入骨替代物而受到任何有害影响。尽管这些系列中的病例数有限,但TGF-β1、人纤维蛋白胶和NCS的组合代表了一个有趣的进展,尽管临床结果仍可改善。这项技术成功的重要因素似乎是生物材料的稳定、周围组织的质量和无菌状态以及生长因子的剂量。